Background Myasthenia gravis (MG) patients are reported to have a high risk of other autoimmune diseases (ADs), and thymectomy may increase the risk further. A cohort of MG patients in which thymectomy was performed were investigated to analyze the prevalence, types and features of the new onset ADs. Methods Consecutive patients with MG who underwent thymectomy at Beijing Hospital between January 2012 and August 2021 were retrospectively enrolled. Patients with a postoperative follow‐up period shorter than a year or incomplete clinical records were excluded. Clinical and follow‐up data were collected. Statistical analyses were performed using SPSS version 22.0. Results A total of 445 patients were included in this study. The median follow‐up period was 72 months (range, 12–135 months). A total of 63 (14.2%) MG patients had concurrent ADs. The incidence rate was higher than the background prevalence of population (5%), and also higher than that of a former Chinese MG cohort (11.6%). A total of 47 patients (10.6%) were diagnosed with ADs before thymectomy, and 19 (4.3%) developed a new AD after thymectomy. The most common types of new onset ADs after thymectomy were Hashimoto's thyroiditis and rheumatoid arthritis (RA), which were different from those before thymectomy (hyperthyroidism and Hashimoto's thyroiditis). The incidence rate of new onset RA (1.35%) was higher than the frequency of RA before thymectomy (0.45%), and also higher than the incidence rate in a Chinese MG cohort (0.5%). There was a higher proportion of female patients (p = 0.026) with postoperative ADs. A younger age at operation may increase the risk of nonthymoma MG patients (p = 0.040) developing ADs. The postoperative treatment effect of MG was similar between patients with and without new onset ADs (p > 0.05). Conclusions We observed a higher incidence rate of autoimmune diseases, especially rheumatoid arthritis, in MG patients after thymectomy. The most common types of ADs after thymectomy were different from those before thymectomy. New onset ADs tended to occur in female and young nonthymoma MG patients. The postoperative effect of MG was not related with the new occurrence of ADs.

Background: People with arteriosclerotic cardiovascular diseases (ASCVD) frequently use antithrombotic agents and statins. The objective of the study was to explore the prevalence and risk factors of cerebral microbleeds (CMB) in elderly Chinese people with ASCVD.Methods: We prospectively and continuously enrolled 755 participants (≥ 65 years old) in Beijing hospital’s health checkup center from February 1, 2019 to June 30, 2021. MRI protocol and imaging analysis were implemented to identify the CMB, the multivariate binary logistic regression analysis was computed the risk factors of CMB.Results: The average age was 74.95 ± 9.54 years, and the prevalence of CMB was 37.9%. Of those with CMB, 65.0% had strictly lobar CMB, 15.7% had strictly deep CMB, and 19.2% had mixed CMB. Age (odds ratio (OR) 1.43, 95% confidence interval (CI) 1.18–1.73, p < 0.0001), statin use (OR 1.58, 95% CI 1.07–2.32, p = 0.02), and lacunes (OR 1.72, 95% CI 1.09–2.71, p = 0.021) were associated with any CMB. Age (OR 1.34, 95% CI 1.10–1.63, p < 0.0001), statin use (OR 1.72, 95% CI 1.15–2.57, p = 0.008), and white matter hyperintensities (OR 1.68, 95% CI 1.15–2.46, p = 0.008) were associated with lobar CMB. Only lacunes were associated with deep CMB (OR 3.29, 95% CI 1.85–5.87, p < 0.001). Antithrombotic drug use was not associated with CMB (OR 1.16, 95% CI 0.79–1.71, p = 0.457), lobar CMB (OR 1.02, 95% CI 0.68–1.53, p = 0.908), or deep CMB (OR 1.39, 95% CI 0.79–2.44, p = 0.254).Conclusion: Statin use was correlated with lobar CMB but not deep CMB in elderly people with risk factors of ASCVD. In contrast, antithrombotic drug use was not correlated with CMB.

No abstract

No abstract